The estimated Net Worth of Javier B. Szwarcberg is at least 68.5 千$ dollars as of 14 December 2023. Dr Szwarcberg owns over 111,000 units of Spruce Biosciences stock worth over 68,481$ and over the last 3 years he sold SPRB stock worth over 0$.
Dr has made over 1 trades of the Spruce Biosciences stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 111,000 units of SPRB stock worth 52,170$ on 14 December 2023.
The largest trade he's ever made was exercising 111,000 units of Spruce Biosciences stock on 14 December 2023 worth over 52,170$. On average, Dr trades about 15,857 units every 0 days since 2022. As of 14 December 2023 he still owns at least 145,705 units of Spruce Biosciences stock.
You can see the complete history of Dr Szwarcberg stock trades at the bottom of the page.
Dr. Javier Szwarcberg M.D., M.P.H. is the CEO & Director at Spruce Biosciences.
Javier's mailing address filed with the SEC is C/O SPRUCE BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Spruce Biosciences have traded over 10,017,426$ worth of Spruce Biosciences stock and bought 4,788,400 units worth 38,247,728$ . The most active insiders traders include Holdings A/S Novo、Bali Muralidhar、Niall O'donnell. On average, Spruce Biosciences executives and independent directors trade stock every 57 days with the average trade being worth of 210,541$. The most recent stock trade was executed by Holdings A/S Novo on 21 March 2024, trading 465,021 units of SPRB stock currently worth 348,766$.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Spruce Biosciences executives and other stock owners filed with the SEC include: